4/3
01:00 am
ipha
Innate Pharma to Participate in the Kempen Life Sciences Conference
Low
Report
Innate Pharma to Participate in the Kempen Life Sciences Conference
4/2
04:40 am
ipha
Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report [Yahoo! Finance]
Low
Report
Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report [Yahoo! Finance]
4/2
04:00 am
ipha
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
Low
Report
Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report
3/27
02:17 am
ipha
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target [Yahoo! Finance]
Low
Report
How Innate Pharma (ENXTPA:IPH) Story Is Shifting Around 2026 Catalysts And €8 Target [Yahoo! Finance]
3/26
04:47 pm
ipha
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/26
04:10 am
ipha
Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M [Seeking Alpha]
Low
Report
Innate Pharma GAAP EPS of -€0.55, revenue of €9.01M [Seeking Alpha]
3/26
02:26 am
ipha
Innate Pharma Reports Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
Low
Report
Innate Pharma Reports Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
3/26
02:00 am
ipha
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Low
Report
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
3/14
06:58 am
ipha
Innate Pharma (IPHA) was upgraded by BTIG Research to "strong-buy".
Medium
Report
Innate Pharma (IPHA) was upgraded by BTIG Research to "strong-buy".
3/12
08:03 am
ipha
Innate Pharma (IPHA) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
Medium
Report
Innate Pharma (IPHA) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
2/26
03:36 am
ipha
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model [Yahoo! Finance]
Low
Report
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model [Yahoo! Finance]
2/19
01:26 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 [Yahoo! Finance]
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 [Yahoo! Finance]
2/19
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
2/18
01:18 am
ipha
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
2/18
01:00 am
ipha
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
Low
Report
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
1/24
05:08 am
ipha
Innate Pharma (NASDAQ:IPHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Innate Pharma (NASDAQ:IPHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/7
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025